Table 1.
Parameters of the univariate analysis of clinicopathological factors
| Explicative variables | Relative risk (95% CI) | p-value |
|---|---|---|
| Tumor size | 2.04 (1.412–2.95) | 0.00015 |
| Grade 1 | - | - |
| Grade 2 | 1.38 (0.30–6.30) | 0.679 |
| Grade 3 | 2.92 (0.63–13.54) | 0.171 |
| Relapse | 14.95 (5.67–39.44) | <0.0001 |
| EBV-T + | 0.795 (0.291–2.173) | 0.65 |
| EBV-P + | 1.05 (0.44–2.51) | 0.91 |
| ER/PR positive | 0.48 (0.19–1.20) | 0.116 |
| HER-2 positive | 2.71 (0.795–9.21) | 0.111 |
| Lymph node invasion | 6.32 (2.31–17.3) | 0.0003 |
| Anti-ZEBRA antibody titration | 4,63 (1.75–12.23) | 0.002 |
EBV: Epstein-Barr virus; T+: detected in tumors; P+: detected in PBMCs; ER/PR: estrogen/progesterone receptor; HER-2: human epidermal growth factor receptor 2; anti-ZEBRA: antibodies to BamH1 Z Epstein-Barr replication activator.